T cell receptor knockout engineered immune cells that are believed to have chimeric antigen receptors that bind to CD123 for the treatment of dendritic cell neoplasms or recurrent / intractable acute myelogenous lymphoma of germ plasm cells.

摘要

The present invention more particularly relates to a scFV derived from a CD123 monoclonal antibody, wherein the extracellular ligand binding confers specific immunity against CD123-positive cells, wherein the reactivity towards CD123-expressing cells and the immunocyte specificity TCR KO - or TCR KO and dCK KO - engineered immune cells expressing chimeric antigen receptors (CAR) specific for CD123, a recombinant chimeric protein that can be redirected. Engineered immune cells that are believed to have such CD123 CARs are particularly suitable for treating dendritic cell neoplasms of relapsed intractable AML and protoplasmic cells, and for use as pre-bone marrow transplantation therapy.